Pharma major Venus Remedies on Monday said it has expanded the reach of its oncology drugs in the Asia Commonwealth of Independent States (CIS) region with marketing authorisations from Ukraine for three cancer drugs-- paclitaxel, oxaliplatin and irinotecan.
Saransh Chaudhary, President, Global Critical Care, Venus Remedies, said, "These marketing approvals mark a significant milestone in our global expansion strategy. We are looking forward to introducing the entire range of our oncology products in Ukraine in due course, thereby contributing to the advancement of healthcare and making a positive impact on people's lives." With over two decades of presence in the Ukrainian market, the company has 57 product registrations in Ukraine.
"This achievement has further strengthened our position in the international pharmaceutical market. It also exemplifies our dedication to advancing healthcare solutions for diverse populations," said Aditi K Chaudhary, President, International Business, Venus Remedies.
Its total volume of exports to Ukraine stands at USD 2.20 million. By strengthening its product portfolio in Ukraine, the company aims to increase this figure by 20 per cent in the next one year, a company statement said.
Venus Remedies is awaiting approval from Ukraine on another 10 applications for marketing authorisations.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
